Sulthiame

Summary

Sulthiame (CHEMBL328560) is an approved small molecule (ATC N03AX03); indicated across 2 conditions including epilepsy and obstructive sleep apnea syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AX03
• Indications: 2 conditions
• Clinical trials: 4
• Chemistry: 290.4 Da · C10H14N2O4S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL328560
Name	Sulthiame
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5356
ATC	N03AX03
Molecular formula	C10H14N2O4S2
Molecular weight	290.4
InChIKey	HMHVCUVYZFYAJI-UHFFFAOYSA-N

SMILES: C1CCS(=O)(=O)N(C1)C2=CC=C(C=C2)S(=O)(=O)N

IUPAC name: 4-(1,1-dioxothiazinan-2-yl)benzenesulfonamide

Also known as: Conadil, Ospolot, RIKER 594, RIKER-594, Sulthiame, Sultiame, Sultiamo, Trolone, sulthiame, SULTHIAME, SID170465788, Sulfonamides

Patent coverage: 1,088 distinct patent families (4,563 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Carbonic anhydrase 2, Carbonic anhydrase 7, Kappa-type opioid receptor, Carbonic anhydrase 1, Carbonic anhydrase 6, Carbonic anhydrase 9, Carbonic anhydrase, Beta-carbonic anhydrase 1, Carbonic anhydrase, Carbonic anhydrase 15.

Bioactivity

ChEMBL activities: 64 potent at pChembl ≥ 5 of 65 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CA7	8.22	Ki	6	nM	CHEMBL_ACT_29315988
CA2	8.15	Ki	7	nM	CHEMBL_ACT_23191259
CA2	8.15	Ki	7	nM	CHEMBL_ACT_29315970
CA2	8.05	Ki	9	nM	CHEMBL_ACT_12161324
CA2	8.05	Ki	9	nM	CHEMBL_ACT_12655973
CA2	8.05	Ki	9	nM	CHEMBL_ACT_13286831
CA2	8.05	Ki	9	nM	CHEMBL_ACT_13866470
CA2	8.05	Ki	9	nM	CHEMBL_ACT_14661467
CA2	8.05	Ki	9	nM	CHEMBL_ACT_15108420
CA2	8.05	Ki	9	nM	CHEMBL_ACT_15143691
CA2	8.05	Ki	9	nM	CHEMBL_ACT_15170048
CA2	8.05	Ki	9	nM	CHEMBL_ACT_15177705
CA2	8.05	Ki	9	nM	CHEMBL_ACT_15674571
CA2	8.05	Ki	9	nM	CHEMBL_ACT_16390810
CA2	8.05	Ki	9	nM	CHEMBL_ACT_16415183
CA2	8.05	Ki	9	nM	CHEMBL_ACT_16451229
CA2	8.05	Ki	9	nM	CHEMBL_ACT_16478450
CA2	8.05	Ki	9	nM	CHEMBL_ACT_16519998
CA2	8.05	Ki	9	nM	CHEMBL_ACT_17997781
CA2	8.05	Ki	9	nM	CHEMBL_ACT_18160121
CA2	8.05	Ki	9	nM	CHEMBL_ACT_19413185
CA2	8.05	Ki	9	nM	CHEMBL_ACT_2421914
CA2	8.05	Ki	9	nM	CHEMBL_ACT_2494436
CA2	8.05	Ki	9	nM	CHEMBL_ACT_2496793
CA2	8.05	Ki	9	nM	CHEMBL_ACT_2525224
CA2	8.05	Ki	9	nM	CHEMBL_ACT_2684142
CA2	8.05	Ki	9	nM	CHEMBL_ACT_2917441
CA2	8.05	Ki	9	nM	CHEMBL_ACT_2943549
CA2	8.05	Ki	9	nM	CHEMBL_ACT_5131555
CA2	8.05	Ki	9	nM	CHEMBL_ACT_6320723

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474
obstructive sleep apnea syndrome	2	MONDO:0007147	EFO:0003918

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
Not specified	2
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05236842	PHASE2	COMPLETED	Efficacy, Safety and Tolerability of Sulthiame in Patients With Obstructive Sleep Apnea (OSA)
NCT03400189	PHASE1	COMPLETED	Pharmacokinetics and Tolerability of Sulthiame
NCT05885646	Not specified	RECRUITING	Effect of Sulthiame on EEG in Childhood Epilepsy Syndromes
NCT03196466	Not specified	COMPLETED	Population Pharmacokinetics of Antiepileptic in Pediatrics

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).